Method for Activating Dendritic Cells

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent presents a method for activating dendritic cells in vitro by exposing them to a substrate surface coated with a specific poly(glycidyl ether) (PGE) derivative. The PGE-coated substrate can take the form of a gel or a brush structure, which selectively trigger maturation and activation of dendritic cells, resulting in beneficial immunomodulatory and tissue repair effects. The invention also describes the medical uses of these activated dendritic cells or PGE-coated materials, such as using them as implants, patches, or as part of in vitro and in vivo therapies for tissue regeneration and immune modulation.

Use CasesContent extracted from patent full text and abstract with AI.

• Production of activated dendritic cells for immunotherapies (e.g., cancer vaccines, autoimmune disease treatment)
• Development of advanced in vitro testing platforms for drug and chemical safety assessment, reducing the need for animal testing
• Regenerative medicine applications, including implants or patches that stimulate tissue repair (e.g., for skin, heart, cartilage, joint, liver, or brain regeneration after injury or disease)
• Wound healing applications to enhance the body's natural repair mechanisms
• Use as a growth factor source in cell culture or clinical treatments
• Immune modulation in patients needing regulated immune response, such as during cytokine storm or immune-related complications

BenefitsContent extracted from patent full text and abstract with AI.

• Enables reliable, controlled, and animal-free activation of dendritic cells in vitro
• Offers a new tool for producing dendritic cells with enhanced immune and tissue-repair functions
• Reduces reliance on traditional immune cell activators (e.g., bacterial products like LPS), which can have unwanted side effects
• Synthetic PGE coatings are biocompatible, non-toxic, and can be finely tuned for different immunological outcomes
• Can improve success and compatibility of autologous cell therapies by activating a patient's own dendritic cells and re-implanting them
• Versatile platform: can be applied to medical devices, implants, patches, or used in cell culture systems
• Promotes both immune response and tissue regeneration, depending on surface structure (gel vs. brush)

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method for activating dendritic cells in vitro, comprising the following steps: a) providing a substrate, wherein a surface of the substrate comprises at least one poly(glycidyl ether) derivative according to general formula (I); b) contacting the substrate with a dendritic cell in an isosmotic aqueous solution or buffer.